Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913 Redazione 3 Giugno 2021 ...
Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML Redazione 27 Maggio 2021 ...
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice Redazione 27 Maggio 2021 ...
Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies Redazione 27 Maggio 2021 ...
Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup Redazione 27 Maggio 2021 ...
Screening and monitoring of the BTKC481S mutation in a real‐world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy Redazione 27 Maggio 2021 ...
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial Redazione 27 Maggio 2021 ...
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant Redazione 20 Maggio 2021 ...
Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia Redazione 13 Maggio 2021 ...
